Huadong Medicine’s HDM1005 Receives NMPA Approval for MAFLD/MASH Clinical Trial
Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval...
Cygenta Partners with IZVARINO Pharma for Comprehensive CDMO Services
Cygenta, a cell and gene therapy (CGT) focused Contract Development and Manufacturing Organization (CDMO) based...
Pfizer Collaborates with Atavistik Bio to Discover Allosteric Therapeutics
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a research collaboration with compatriot firm...
NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD
The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum...
Genesis MedTech’s iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery
Singapore-based medical device company Genesis MedTech has announced that it has received marketing approval from...
Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...
Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing
Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory...
Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines
China-based Brii Biosciences Ltd (HKG: 2137) has announced its intention to acquire the intellectual property...
Shanghai Pharmaceuticals Halts Development of I001-B, I022, and C012 in the US
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has declared the termination of clinical trials...
Astellas Pharma’s Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer
China’s National Medical Products Administration (NMPA) has indicated on its website that Japan-based Astellas Pharma...
Sichuan Kelun-Biotech’s Ketailai Receives NMPA Approval for Nasopharyngeal Carcinoma Treatment
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received marketing...
Sino Biopharmaceutical’s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its...
HutchMed’s Orpathys Receives Priority Review for NSCLC Treatment in China
HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that the China National Medical Products...
Innovent Biologics Strikes Licensing Deal with Roche for IBI3009 ADC
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a significant licensing agreement with Swiss pharmaceutical...
Maxvax Biotechnology Secures RMB 200 Million in Convertible Bonds Financing
Immunotherapy biotech company Maxvax Biotechnology, based in Chengdu, has announced the successful closure of a...
Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has reached an agreement to divest its...
Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China
US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of...
Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema
Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...